Are oncoantigens suitable targets for anti-tumour therapy?
Nat Rev Cancer
; 7(9): 707-13, 2007 09.
Article
en En
| MEDLINE
| ID: mdl-17700704
When a vaccine-elicited immune response is directed against oncoantigens--proteins required for the neoplastic process--the chance that the tumour will evade the vaccine should be reduced. But how can these causal oncoantigens be identified? One approach is to find tumour-associated and microenvironment-associated oncoantigens required for progression from one tumour stage to the next by comparing gene signatures isolated from the different stages of tumour progression in cancer-prone transgenic mice. Mouse oncoantigens subsequently shown to be involved in human cancer can then be validated in mouse vaccination experiments. This provides the groundwork for the rational design of cancer vaccines for clinical trials.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Diseño de Fármacos
/
Vacunas contra el Cáncer
/
Antígenos de Neoplasias
/
Neoplasias
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Nat Rev Cancer
Asunto de la revista:
NEOPLASIAS
Año:
2007
Tipo del documento:
Article
País de afiliación:
Italia
Pais de publicación:
Reino Unido